Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death
Portfolio Pulse from
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares dropped over 21% after a patient death linked to its gene therapy ELEVIDYS for Duchenne muscular dystrophy. The incident raises new safety concerns, as the severity of the liver injury had not been previously reported.
March 18, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics faces significant stock price decline after a patient death linked to its gene therapy ELEVIDYS, raising new safety concerns.
The death of a patient treated with ELEVIDYS has led to a 21% drop in Sarepta's stock price, indicating a strong negative market reaction. The severity of the liver injury, not previously reported, raises significant safety concerns that could impact future sales and regulatory scrutiny.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100